About Inovalis Real Estate Investment Trust
Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: TSE
- Symbol: INO
- CUSIP:
Key Metrics:
- Previous Close: $0.00
- 50 Day Moving Average: $N/A
- 200 Day Moving Average: $N/A
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Market Cap: $N/A
Additional Links:
Consensus Ratings for Inovalis Real Estate Investment Trust (TSE:INO) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.| Ratings Breakdown: | 1 Hold Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Inovalis Real Estate Investment Trust (TSE:INO)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 5/25/2016 | National Bank Financial | Downgrade | Outperform Market Weight -> Sector Perform Market Weight | |  |
| 3/28/2016 | Desjardins | Downgrade | Buy -> Hold | | |
(Data available from 9/30/2014 forward)
Earnings History for Inovalis Real Estate Investment Trust (TSE:INO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/18/2014 | | $0.22 | $0.22 | | | View | N/A | |
| 5/9/2014 | | $0.20 | $0.23 | | | View | N/A | |
| 3/22/2014 | | $0.20 | $0.24 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Inovalis Real Estate Investment Trust (TSE:INO)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2016 | 1 | $0.25 | $0.25 | $0.25 |
| Q2 2016 | 2 | $0.23 | $0.24 | $0.24 |
| Q3 2016 | 2 | $0.20 | $0.23 | $0.22 |
| Q4 2016 | 1 | $0.21 | $0.21 | $0.21 |
| Q1 2017 | 1 | $0.25 | $0.25 | $0.25 |
| Q2 2017 | 1 | $0.26 | $0.26 | $0.26 |
| Q3 2017 | 1 | $0.26 | $0.26 | $0.26 |
| Q4 2017 | 1 | $0.26 | $0.26 | $0.26 |
(Data provided by Zacks Investment Research)
Dividend History for Inovalis Real Estate Investment Trust (TSE:INO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Inovalis Real Estate Investment Trust (TSE:INO)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Inovalis Real Estate Investment Trust (TSE:INO)
Inovalis Real Estate Investment Trust (TSE:INO) Chart for Friday, September, 30, 2016
